Celgene Corporation

Gang Lu

Antonia Lopez-Girona

Joshua Hansen

Ellen Filvaroff

Philip Chamberlain

Brian Edwin Cathers

Sophie Perrin-Ninkovic

Michael Pourdehnad

Chin-Chun Lu

Kyle MacBeth

Lilly L Wong

Soraya Carrancio

Irit Rappley

Sophie Peng

Frans Baculi

Matthew Daniel Correa

Mark A Nagy

Yu Pu

Laurie Ann LeBrun

Tonia J Buchholz

Courtney G Havens

Maria Soraya Carrancio Anton

Jinhong Fan

Paul Hollenbach

Katherine Northcote

Mary Matyskiela

Suzana Sturlini Couto

Katherine Stamp

Philip J Sherratt

Julia Hui

Emily Pace

Sheena Yao

Naijun Wu

Rajan Gupta

Peng Wang

Provided herein are 1-oxo-isoindoline-5-carboxamide compounds having the following structure:

Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith

A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is a compound of Formula I:

Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies

Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.

Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases

A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.

Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile

Provided herein are methods of treating, preventing, managing, and/or ameliorating leukemia or myelodysplastic syndrome comprising administering 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof to a patient.

Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is a compound of Formula I: 

A method of screening a cereblon modifying compound for treating a disease or disorder, comprising: obtaining a sample; determining a first protein level of SALL; administering the cereblon modifying compound to the sample; determining a second protein level of SALL; comparing the first level and the second protein level of SALLto determine if the cereblon modifying compound induces degradation of SALL; and selecting the cereblon modifying compound that does not induce degradation of SALL

Methods for screening cereblon modifying compounds

Provided herein are 1-oxo-isoindoline-5-carboxamide compounds having the following structure: 

Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile

Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

Growing community of inventors

San Diego, CA, United States of America

Gang Lu